GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Positive Phase III results for Nucala in COPD – Company Announcement
GSK announces positive phase III trial results for Nucala (mepolizumab) in COPD, showing significant reduction in exacerbations.
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs
GSK's MATINEE Phase 3 trial showed Nucala (mepolizumab) significantly reduced COPD exacerbations in type 2 inflammation patients, with safety consistent with known profile. Nucala is not yet indicated for COPD but contributed 6% to GSK's 2023 sales.
GSK's asthma blockbuster Nucala secures win in COPD Phase III trial
GSK's asthma drug Nucala met primary endpoint in Phase III COPD trial, showing reduced exacerbations when added to inhaled maintenance therapy. GSK plans EU and Canada regulatory submission in 2025, with ongoing data analysis. Nucala, an IL-5 antagonist, generated £1.6bn in 2023 and is predicted to reach $2.35bn by 2026.
GSK announces Phase III trial of Nucala met primary endpoint
GSK's MATINEE phase III trial showed Nucala, targeting IL-5, significantly reduced COPD exacerbations in adults with type 2 inflammation, with consistent safety.
GSK Asthma Drug Shows Promise in Treating Chronic Lung Disease
GSK's Nucala showed significant reduction in COPD flare-ups in a trial, potentially expanding its use beyond asthma treatment.
Phase III Trial Of Nucala In Chronic Obstructive Pulmonary Disease Meets Primary Endpoint
GSK announced positive results from the MATINEE phase III trial evaluating Nucala, an IL-5-targeting monoclonal antibody, in adults with COPD, showing a significant reduction in moderate/severe exacerbations. The preliminary safety results align with Nucala's known profile.
GSK reports positive results from phase III trial of Nucala in COPD
GSK announces positive results of MATINEE trial, showing Nucala (mepolizumab) significantly reduces COPD exacerbations in type 2 inflammation patients.
© Copyright 2025. All Rights Reserved by MedPath